Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as C$0.07 and last traded at C$0.07, with a volume of 3,000 shares traded. The stock had previously closed at C$0.07.
Resverlogix Stock Performance
The stock has a market cap of C$25.82 million, a PE ratio of -1.88 and a beta of -0.11. The firm has a 50-day moving average price of C$0.09 and a 200-day moving average price of C$0.10. The company has a debt-to-equity ratio of -82.47, a quick ratio of 0.04 and a current ratio of 0.04.
Resverlogix Company Profile
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Further Reading
- Five stocks we like better than Resverlogix
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
